Related Experiment Videos
Low pyridoxal 5'-phosphate is associated with increased risk of coronary artery disease
Ping-Ting Lin1, Chien-Hsiang Cheng, Yung-Po Liaw
1School of Nutrition, Chung Shan Medical University, Taichung, Taiwan.
Insights
Low plasma pyridoxal 5'-phosphate (PLP), a marker of vitamin B6 status, is linked to increased coronary artery disease (CAD) risk. Combined low PLP and abnormal lipids further elevate this risk.
Area of Science:
- Biochemistry
- Cardiovascular Medicine
- Nutritional Science
Background:
- Vitamin B6, in its active form pyridoxal 5 '-phosphate (PLP), plays a crucial role in metabolic processes.
- Dyslipidemia and inflammation are established risk factors for coronary artery disease (CAD).
- The interplay between vitamin B6 status, lipid profiles, and CAD risk requires further elucidation.
Purpose of the Study:
- To investigate the association between plasma PLP levels and lipid profiles.
- To estimate the relationship between plasma PLP status and the risk of developing CAD.
- To determine if lipid profiles modify the association between PLP and CAD risk.
Main Methods:
- Case-control study design with 184 CAD patients (>=70% coronary artery stenosis) and 516 healthy controls.
- Measurement of plasma PLP, homocysteine, high-sensitivity C-reactive protein, and comprehensive lipid profiles.
- Statistical analysis to assess the association between PLP levels and CAD risk, adjusting for covariates.
Main Results:
- Subjects with plasma PLP <30 nmol/L had a significantly higher risk of CAD (OR, 1.85; 95% CI, 1.16-2.95) after adjusting for homocysteine and hs-CRP.
- The association between PLP and CAD risk remained significant after adjusting for individual lipid parameters.
- Concomitant low PLP and abnormal lipid levels markedly amplified the risk of CAD.
Conclusions:
- Borderline vitamin B6 deficiency (plasma PLP <30 nmol/L) is a significant risk factor for CAD.
- The synergistic effect of low PLP and dyslipidemia substantially increases CAD risk.
- Maintaining adequate vitamin B6 status may be important for cardiovascular health, particularly in individuals with lipid abnormalities.
Objective:
The purpose of this study was to investigate the association between plasma pyridoxal 5'-phosphate (PLP) status and lipid profiles and to estimate the relation to the risk of coronary artery disease (CAD).
Methods:
Patients who were identified by cardiac catheterization as having > or =70% stenosis of one major coronary artery were assigned to the case group (n = 184). The control group (n = 516) was comprised of healthy individuals with normal blood biochemical values. Plasma PLP, homocysteine, high-sensitivity C-reactive protein, lipid profiles (total cholesterol, low-density lipoprotein, high-density lipoprotein, very low-density lipoprotein, and triacylglycerol) were determined.
Results:
Subjects with a plasma PLP level <30 nmol/L exhibited a significantly increased risk of CAD compared with subjects with a plasma PLP level > or =30 nmol/L (odds ratio, 1.85; 95% confidence interval, 1.16-2.95) after adjusting for homocysteine and high-sensitivity C-reactive protein. The association between PLP and the risk of CAD remained significant after each lipid profile was additionally adjusted. In addition, the combined presence of low PLP level and an abnormal lipid level increased the risk of CAD to an even greater degree.
Conclusions:
A borderline vitamin B6 deficiency (plasma PLP concentration <30 nmol/L) is strongly associated with the risk of CAD. The combined presence of low PLP and abnormal lipid levels increased the risk of CAD even further.
Related Concept Videos
Coronary Artery Disease I: Introduction
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease II: Pathophysiology
Vitamins
Drug Toxicity: Risk factors
Peripheral Artery Disease I: Introduction